Atrogi宣布《细胞》论文强调了针对肌肉的疗法在代谢疾病中的变革潜力-动脉网

Atrogi announces Cell paper highlighting transformative potential of muscle-targeted therapy in metabolic disease

CISION 等信源发布 2025-06-23 23:00



可切换为仅中文







Atrogi's breakthrough discovery enables chronic use of next-generation, highly selective β2-agonists for the first time in metabolic disease

阿特罗吉的突破性发现首次实现了在代谢疾病中长期使用下一代高选择性β2-激动剂。

First-in-class oral therapy ATR-258 mimics the effects of exercise – driving fat loss, increasing muscle, and improving metabolism – with broad potential in obesity, diabetes, and age-related muscle loss

首创口服疗法ATR-258模拟运动效果——促进脂肪减少、增加肌肉、改善代谢——在肥胖、糖尿病和与年龄相关的肌肉流失方面具有广泛潜力。

ATR-258 is set to enter Phase 2 trials to confirm its ability to deliver exercise-like benefits, including fat loss, improved muscle strength, and better metabolic control, alone or in combination with

ATR-258 即将进入第 2 阶段试验，以确认其单独使用或与其他方法结合使用时，提供类似运动的益处的能力，这些益处包括脂肪减少、肌肉力量增强和更好的代谢控制。

GLP-1

therapies

疗法

STOCKHOLM

斯德哥尔摩

，

June 23, 2025

2025年6月23日

/PRNewswire/ -- Atrogi AB, a clinical-stage biotechnology company pioneering muscle-targeted therapies, today announces the publication of a landmark study in the prestigious scientific journal

/PRNewswire/ -- 致力于开发肌肉靶向疗法的临床阶段生物技术公司Atrogi AB今日宣布，在著名科学期刊上发表了一项具有里程碑意义的研究。

Cell

细胞

, titled '

，标题为‘

GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity

用于治疗2型糖尿病和肥胖症的GRK偏向性肾上腺素能激动剂

.' This paper highlights Atrogi's first-in-class oral β2-adrenergic receptor agonist, ATR-258, which precisely activates skeletal muscle metabolism through novel GRK2-biased signaling. This transformative approach enhances glucose uptake and improves body composition by reducing fat and preserving lean muscle without the cardiovascular risks typically associated with β2-agonists..

本文重点介绍了Atrogi公司首创的口服β2-肾上腺素受体激动剂ATR-258，它通过新颖的GRK2偏向性信号传导精确激活骨骼肌代谢。这种变革性的方法增强葡萄糖摄取并改善身体组成，减少脂肪、保留瘦肌肉，且没有通常与β2-激动剂相关的心血管风险。

This marks a pivotal step in unlocking the full therapeutic potential of muscle-targeted β2-agonists

这标志着在充分释放靶向肌肉的β2-激动剂的治疗潜力方面迈出了关键一步。

，

said Professor

教授说

Tore Bengtsson

托雷·本特松

, senior author of the study, Chief Scientific Officer, and Founder of Atrogi

，该研究的资深作者，Atrogi公司的首席科学官及创始人

. '

。'

Our research elucidates a novel signaling pathway that avoids the cardiac side effects of β2-agonists and provides compelling proof that ATR-258 can actively reshape body composition – reducing fat while preserving muscle mass – all without requiring dietary restriction. That's an unprecedented therapeutic profile.' .

我们的研究阐明了一种新的信号通路，它可以避免β2-激动剂的心脏副作用，并提供了令人信服的证据，证明ATR-258可以积极重塑身体组成——减少脂肪的同时保留肌肉质量——而且无需饮食限制。这是一个前所未有的治疗特性。

Additionally, when combined with

此外，当结合

GLP-1

receptor agonists, ATR-258 avoids the critical shortcomings of current obesity and diabetes treatments by preventing the muscle loss typically associated with these therapies.

通过防止与这些疗法通常相关的肌肉损失，ATR-258避免了当前肥胖症和糖尿病治疗的关键缺陷。

Associate Professor

副教授

Morten Hostrup

莫滕·霍斯特鲁普

from the

来自

University of Copenhagen

哥本哈根大学

added

已添加

: '

This development offers patients a unique treatment option that does not require compromising muscle in the pursuit of weight loss. The potential applications of ATR-258 extend well beyond obesity and diabetes, encompassing a range of muscle-wasting conditions. By preserving muscle mass while supporting improved glucose regulation, ATR-258 may represent a significant advancement in therapeutic approaches across multiple clinical areas.

这种发展为患者提供了一种独特的治疗选择，在追求减重的同时无需牺牲肌肉。ATR-258 的潜在应用远不止于肥胖和糖尿病，还涵盖了一系列消耗肌肉的病症。通过在支持改善葡萄糖调节的同时保留肌肉质量，ATR-258 可能代表了在多个临床领域治疗手段的重大进步。

。'

The study will appear in the

该研究将出现在

September 2025

2025年9月

issue of

问题

Cell

细胞

and includes co-authors from multiple leading institutions across

其中包括来自多个领先机构的合著者

Europe

欧洲

and

和

Australia

澳大利亚

. The breakthrough is the result of a long-term academic and industry collaboration led by Atrogi, together with scientists from

这一突破是Atrogi领导的长期学术和行业合作的结果，同时也离不开科学家们的共同努力，

Karolinska Institutet

卡罗林斯卡学院

，

Stockholm University

斯德哥尔摩大学

, the

，这个

University of Copenhagen

哥本哈根大学

, University of Nottingham, Monash University, and the

诺丁汉大学、莫纳什大学，以及

University of Queensland

昆士兰大学

. A key contributor was Assistant Professor

关键贡献者之一是助理教授

Shane Wright

肖恩·赖特

的

Karolinska Institutet

卡罗林斯卡学院

, a leading expert in G protein–coupled receptor (GPCR) signaling, who co-elucidated the GRK2-biased mechanism that underpins ATR-258's muscle-specific effects.

，G蛋白偶联受体（GPCR）信号传导领域的权威专家，他共同阐明了GRK2偏向机制，该机制是ATR-258肌肉特异性效应的基础。

Key findings from the

主要发现来自

Cell

细胞

study include:

研究包括：

Development of GRK2-biased β2-agonists with potent effects on skeletal muscle metabolism and glucose uptake

开发对GRK2有偏倚的β2-激动剂，对骨骼肌代谢和葡萄糖摄取有显著效果

Prevention of muscle loss and improvement of metabolic health in preclinical models of type 2 diabetes, obesity, sarcopenia, and

在2型糖尿病、肥胖症、肌肉减少症和的临床前模型中预防肌肉流失并改善代谢健康

GLP-1

–induced muscle wasting

诱导的肌肉萎缩

Favorable safety profile confirmed in long-term rodent and canine toxicology studies

长期啮齿动物和犬类毒理学研究证实具有良好的安全性特征

First-in-human trial data demonstrating safety and tolerability in both healthy volunteers and patients with type 2 diabetes

首次人体试验数据证明，在健康志愿者和2型糖尿病患者中均具有安全性和耐受性。

Alexandra Ekman Ryding

亚历山德拉·埃克曼·吕丁

, Chief Executive Officer of Atrogi, said

Atrogi首席执行官表示

：

'We are excited by the findings of this paper which emphatically validate the potential of our novel compound to provide a disease-modifying treatment to those suffering with metabolic disorders. It is a testament to the drive, talent, and dedication of our world-class team that we are now Phase 2 ready.

“我们对这篇论文的发现感到兴奋，它有力地证实了我们的新型化合物为代谢紊乱患者提供疾病修饰治疗的潜力。这是我们世界级团队的动力、才华和奉献精神的证明，我们现在已准备好进入第二阶段。

This proof-of-concept not only validates our approach but also demonstrates the strength of our proprietary discovery engine. It showcases what our broader platform is capable of – unlocking a pipeline of precision therapies that can address major unmet needs in metabolic and muscle-related diseases.'.

这一概念验证不仅证实了我们的方法，还展示了我们专有发现引擎的强大功能。它体现了我们更广泛平台的能力——解锁一条精准治疗的渠道，可以满足代谢和肌肉相关疾病中的重大未满足需求。

In the near term, Atrogi is advancing ATR-258 into Phase 2 clinical trials, which will evaluate its ability to deliver exercise-like benefits, including fat loss, improved muscle strength and function, and better metabolic control – both as a monotherapy and in combination with

短期内，Atrogi公司正将ATR-258推进到二期临床试验，以评估其提供类似运动益处的能力，包括减脂、提高肌肉力量和功能以及更好的代谢控制——无论是作为单一疗法还是联合疗法。

GLP-1

receptor agonists.

受体激动剂。

About Atrogi

关于Atrogi

Atrogi AB is a

阿特罗吉公司是一家

Stockholm

斯德哥尔摩

-based clinical-stage biotechnology company focused on developing first-in-class therapies that harness skeletal muscle signaling to treat metabolic diseases. Its lead candidate, ATR-258, is an oral GRK2-biased β2-agonist designed to safely stimulate muscle metabolism and preserve lean mass, offering a novel approach to treating diabetes, obesity, and muscle loss..

基于临床阶段的生物技术公司，专注于开发利用骨骼肌信号传导治疗代谢性疾病的一流疗法。其主要候选药物ATR-258是一种口服GRK2偏向性β2-激动剂，旨在安全刺激肌肉代谢并保持瘦体质量，为治疗糖尿病、肥胖症和肌肉损失提供了新颖的方法。

Atrogi's proprietary compound library, developed under the scientific leadership of Professor

Atrogi的专有化合物库，在教授的科学领导下开发

Tore Bengtsson

托雷·本特松

, serves as the foundation for a broader platform aimed at discovering selective GPCR modulators across multiple disease areas. Learn more at

，作为更广泛平台的基础，该平台旨在发现多个疾病领域的选择性GPCR调节剂。欲了解更多信息，请访问

www.atrogi.com

and on

并且继续

领英

。